Technical Analysis for OPGN - OpGen, Inc.

Grade Last Price % Change Price Change
D 0.49 0.83% 0.00
OPGN closed up 0.83 percent on Monday, March 18, 2024, on 81 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
Earnings due: Mar 27
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
200 DMA Support Bullish 0.00%
Hammer Candlestick Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Fell Below 20 DMA Bearish 0.83%
Wide Bands Range Expansion 0.83%
20 DMA Support Bullish -1.96%
Inside Day Range Contraction -1.96%

   Recent Intraday Alerts

Alert Time
200 DMA Support about 17 hours ago
Gap Up Closed about 17 hours ago
Gap Up Partially Closed about 17 hours ago
2x Volume Pace about 17 hours ago
1.5x Volume Pace about 17 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

OpGen, Inc. Description

OpGen, Inc. operates as an early commercial stage company using molecular testing and bioinformatics to assist healthcare providers to combat multi-drug-resistant bacterial infections. It offers Acuitas multi-drug-resistant organisms (MDRO) gene test, a molecular screening tool that detects 10 critical MDRO genes from 1 patient swab. The company also provides Acuitas CR Elite Test, which adds the ability to procure a standard microbiological culture result that provides additional information about the identified MDRO gene and its antibiotic susceptibility profile. In addition, it develops Acuitas Lighthouse MDRO bioinformatics product, which focuses on providing MDRO molecular information about an individual patient's resistance profile. OpGen, Inc. has a strategic collaboration with Hitachi High-Technologies Corporation to commercialize its genome mapping technology for mapping, assembly, and analysis of human DNA. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Healthcare Providers Antibiotics Informatics Genome Bacterial Infections Bioinformatics Veterinary Medicine Organisms Bacteria Antimicrobial Resistance Evolutionary Biology Multi Drug Resistant Bacterial Infections

Is OPGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.84
52 Week Low 0.165
Average Volume 200,973
200-Day Moving Average 0.48
50-Day Moving Average 0.42
20-Day Moving Average 0.49
10-Day Moving Average 0.51
Average True Range 0.05
RSI (14) 51.46
ADX 22.58
+DI 17.46
-DI 22.00
Chandelier Exit (Long, 3 ATRs) 0.45
Chandelier Exit (Short, 3 ATRs) 0.54
Upper Bollinger Bands 0.59
Lower Bollinger Band 0.40
Percent B (%b) 0.45
BandWidth 39.25
MACD Line 0.02
MACD Signal Line 0.03
MACD Histogram -0.0081
Fundamentals Value
Market Cap 4.86 Million
Num Shares 10 Million
EPS -6.25
Price-to-Earnings (P/E) Ratio -0.08
Price-to-Sales 1.29
Price-to-Book 1.53
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.56
Resistance 3 (R3) 0.55 0.53 0.54
Resistance 2 (R2) 0.53 0.51 0.53 0.54
Resistance 1 (R1) 0.51 0.50 0.49 0.51 0.54
Pivot Point 0.48 0.48 0.47 0.48 0.48
Support 1 (S1) 0.46 0.46 0.44 0.46 0.43
Support 2 (S2) 0.43 0.45 0.43 0.43
Support 3 (S3) 0.41 0.43 0.43
Support 4 (S4) 0.41